cadenas

Innovative Therapies for Children with Cancer in Europe

  • Innovative Therapies
    for Children with Cancer in Europe
  • Contact us

Innovative Therapies for Children with Cancer

  • An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects ≥1 and ≤30 Years of Age with Relapsed/Refractory Precursor B-cell or T cell Acute Lymphoblastic Leukemia

  • A PHASE I/II, MULTICENTER, OPEN-LABEL, MULTI-ARM STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ACTIVITY OF IDASANUTLIN

  • A Phase Ib study of Vyxeos® (liposomal daunorubicin and cytarabine) in combination with Clofarabine in children with relapsed/refractory AML

  • An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Single- Agent Ponatinib for the Treatment of advanced Leukemias or Solid Tumors in Pediatric Participants

  • Phase 1b/2 Study of Carfilzomib in combination with Dexamethasone, Mitoxantrone, PEG-asparaginase, and Vincristine (R3 Induction Backbone) in pediatric subjects with relapsed or refractory Acute Lymphoblastic Leukemia

  • A Prospective, Multicentric Clinical Proof-of-Concept Study to Stratify Targeted Therapies Adapted to Molecular Profiling of Relapsed or Refractory Pediatric Tumors

  • European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors in children

  • Ibrutinib randomized safety and efficacy study in pediatric patients with mature B-cell NHL, including Burkitt lymphoma/Leukemia and Diffuse Large B-cell Lymphoma